Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer (Q33682988)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer |
scientific article |
Statements
1 reference
Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer (English)
1 reference
N Takahashi
1 reference
Y Yamada
1 reference
K Furuta
1 reference
Y Honma
1 reference
S Iwasa
1 reference
A Takashima
1 reference
K Kato
1 reference
T Hamaguchi
1 reference
Y Shimada
1 reference
6 May 2014
1 reference
1 reference
110
1 reference
11
1 reference
2716-2727
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference